Ray: a genotype-agnostic approach to reversing blindness with one-time therapy
With $100M in series A funding, ‘2.0’ gene therapy company aims to treat retinitis pigmentosa using a channelrhodopsin variant designed for greater light sensitivity
A new $100 million series A round will allow Ray to find out whether its gene therapy for retinitis pigmentosa can overcome hurdles that have previously emerged using optogenetics, particularly the low light sensitivity seen with prior approaches.
Seeded by 4BIO Capital, Ray Therapeutics Inc. is the latest company to take an optogenetics approach to treating a major cause of blindness. Rather than correcting one of the many genetic mutations that cause RP, Ray hopes to develop a therapy that works regardless of a patient’s genotype...